drugset / Trial / NCT00371553
Phase-II Study of SU011248 (Sunitinib)in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer
Phase 2
Completed
33 enrolled
British Columbia Cancer Agency
Canadian Urologic Oncology Group · collabGerman Testicular Cancer Study Group · collabNCIC Testis Group · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the activity of SU011248 in subjects with cisplatin-refractory or multiply relapsed germ cell cancer. It is believed that SU011248 treatment may prove to increase disease response.
Timeline
- Start
- 2006-11
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 50 mg | Oral |